SHPH

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - 10-Q Summary

Business Context and Reporting Period

Period: Quarterly report for the three and six months ended June 30, 2025.

Business Overview: Shuttle Pharmaceuticals is a discovery and development-stage biopharmaceutical company focused on developing novel therapies to sensitize cancer cells to radiation therapy. The primary product candidate is Ropidoxuridine, currently in Phase II clinical trials for brain cancer. The company operates as a single segment and has no commercial revenue.

Corporate Status: The company is a "smaller reporting company" and an "emerging growth company." It effectuated a 1-for-25 reverse stock split on June 16, 2025, to regain compliance with Nasdaq listing requirements.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 139% to $6.86 million for the six months ended June 30, 2025, compared to $2.87 million in the prior year period.
  • Research & Development (R&D): Increased 111% to $2.60 million, driven by CRO expenses and clinical trial initiation for Ropidoxuridine.
  • General & Administrative (G&A): Increased 364% to $2.94 million, primarily due to a $2.0 million investor relations consulting fee and increased stock-based compensation.
• Other Income/Expense: Net other income improved significantly to $102,175 (from a loss of $894,765 in 2024). This was driven by a $121,451 gain on the change in fair value of convertible notes and a reduction in interest expense due to the settlement of the Alto Convertible Note.
• Liquidity: Cash balances increased by approximately $4.1 million, resulting from two equity financings in March and June 2025 totaling approximately $8.9 million in net proceeds.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Despite recent cash raises, existing resources are not expected to fund operations and clinical trials for the next twelve months. Continued success depends on raising additional equity or debt financing.
• Financing Activity:
  • March 2025: Public offering raised ~$5.0 million net.
  • June 2025: Private placement raised ~$3.9 million net.
  • Revolving Credit: Entered a $2.0 million revolving note agreement in February 2025 (undrawn as of June 30).
• Unusual Items:
  • Investor Relations Fee: Incurred a $2.0 million expense for IR Agency LLC services in Q2 2025.
  • Stock-Based Compensation: Recorded ~$0.5 million in accelerated stock-based compensation due to the resignation of four board members as a condition of the revolving loan agreement.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of June 30, 2025, citing material weaknesses in accounting transaction processing, segregation of duties, and IT general controls. Remediation efforts are ongoing.
• Legal Contingency: Boustead Securities has asserted a right of first refusal regarding recent financings. The company does not believe a loss is probable or estimable at this time.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion given the "substantial doubt" disclosure and the $2.0 million remaining obligation to the CRO (Theradex).
• Internal Controls: Review the remediation plan for the identified material weaknesses in financial reporting and IT controls.
• Dilution Risk: Assess the impact of outstanding pre-funded warrants (1,158,953 unexercised as of June 30) and convertible notes on future share count.
• Legal Dispute: Monitor the status of the Right of First Refusal claim by Boustead Securities.
• Revenue Timeline: Confirm the schedule for the Phase II clinical trial of Ropidoxuridine, as the company has no revenue and relies entirely on financing.